- evidence of ongoing sars-cov-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay - non-invasive ventilation continuous positive airway pressure/bilevel positive airway pressure (cpap/bipap) or high-flow nasal oxygen therapy (who osci score of 5) - endotracheal intubation and invasive mechanical ventilation (who osci score of ≥6) or admission to intensive care - previous sars-cov-2 infection confirmed by a validated molecular assay or validated antigen assay - any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation - participation in previous clinical trials of sng001 - current or previous participation in another clinical trial where the patient has received a dose of an investigational medicinal product containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study - inability to use a nebuliser with a mouthpiece - inability to comply with the requirements for storage conditions of study medication in the home setting - history of hypersensitivity to natural or recombinant ifn-β or to any of the excipients in the drug preparation - females who are breast-feeding, lactating, pregnant or intending to become pregnant.

- evidence of ongoing sars-cov-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay - non-invasive ventilation continuous positive airway pressure/bilevel positive airway pressure (cpap/bipap) or high-flow nasal oxygen therapy (who osci score of 5) - endotracheal intubation and invasive mechanical ventilation (who osci score of ≥6) or admission to intensive care - previous sars-cov-2 infection confirmed by a validated molecular assay or validated antigen assay - any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation - participation in previous clinical trials of sng001 - current or previous participation in another clinical trial where the patient has received a dose of an investigational medicinal product containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study - inability to use a nebuliser with a mouthpiece - inability to comply with the requirements for storage conditions of study medication in the home setting - history of hypersensitivity to natural or recombinant ifn-β or to any of the excipients in the drug preparation - females who are breast-feeding, lactating, pregnant or intending to become pregnant.

- evidence of ongoing sars-cov-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay - non-invasive ventilation or high-flow oxygen (osci score of 5) - mechanical ventilation (continuous or intermittent continuous positive airway pressure or intubation) or admission to intensive care (osci score of ≥ 6) - previous sars-cov-2 infection confirmed by a validated molecular assay or validated antigen assay - any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation - participation in previous clinical trials of sng001 - current or previous participation in another clinical trial where the patient has received a dose of an investigational medicinal product containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study - inability to use a nebuliser with a mouthpiece - inability to comply with the requirements for storage conditions of study medication in the home setting - history of hypersensitivity to natural or recombinant ifn-β or to any of the excipients in the drug preparation - females who are breast-feeding, lactating, pregnant or intending to become pregnant. - previous sars-cov-2 vaccination

- evidence of ongoing sars-cov-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay - non-invasive ventilation or high-flow oxygen (osci score of 5) - mechanical ventilation (continuous or intermittent continuous positive airway pressure or intubation) or admission to intensive care (osci score of ≥ 6) - previous sars-cov-2 infection confirmed by a validated molecular assay or validated antigen assay - any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation - participation in previous clinical trials of sng001 - current or previous participation in another clinical trial where the patient has received a dose of an investigational medicinal product containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study - inability to use a nebuliser with a mouthpiece - inability to comply with the requirements for storage conditions of study medication in the home setting - history of hypersensitivity to natural or recombinant ifn-β or to any of the excipients in the drug preparation - females who are breast-feeding, lactating, pregnant or intending to become pregnant. - previous sars-cov-2 vaccination